GlenJoelWeissMD

Oncology • Goodyear, AZ

Physician

Join to view full profile

Dr. Weiss is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Weiss' full profile

Already have an account?

Office
14200 W Celebrate Life Way
Goodyear, AZ 85338
Phone+1 623-207-3000

Fax+1 623-321-1528
Is this information wrong?

Education & Training

University of ColoradoFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Colorado School of MedicineFellowship, Hematology and Medical Oncology, 2007
SUNY Health Science Center at BrooklynResidency, Internal Medicine, 2001 - 2004
SUNY Health Science Center at BrooklynInternship, Internal Medicine, 2001 - 2002
Tel Aviv University SacklerClass of 2001
OtherClass of 2001

Certifications & Licensure

MA State Medical License 2018 - 2024
AZ State Medical License 2007 - 2020
CO State Medical License 2004 - 2007
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology
Medical Oncology, Internal Medicine

Clinical Trials

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Mar 01
Completed
Phase 1
Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening Start of enrollment: 2007 Aug 01
Terminated
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Start of enrollment: 2010 Feb 22
Terminated
Phase 2
Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors Start of enrollment: 2009 Nov 01
Completed
Phase 1
An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advance Refractory Cancer Start of enrollment: 2011 Sep 01
Completed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) Start of enrollment: 2011 Sep 20
Completed
Phase 1, Phase 2
Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer Start of enrollment: 2013 Apr 01
Terminated
Phase 2
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors Start of enrollment: 2013 Jun 01
Withdrawn
Not Applicable
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Start of enrollment: 2013 Nov 01
Unknown status
Phase 1, Phase 2
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

2 citations
Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma.
Sujatha Muralidharan, Thibault Kervarrec, Glen J Weiss, Mahtab Samimi> ;Oncotarget. 2022 Jan 1
8 citations
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
Amita Patnaik, Glen J. Weiss, Drew W. Rasco, Lisa Blaydorn, Amy Mirabella, Murali Beeram, Wei Guo, Sharon Lu, Hadi Danaee, Kristen McEachern, Ellie Im, Jasgit C. Sachdev> ;Cancer Chemotherapy and Pharmacology. 2021 Nov 8
3 citations
Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer
Htoo Zarni Oo, Zoltan Lohinai, Nastaran Khazamipour, Joey Lo, Gunjan Kumar, Jessica Pihl, Hans Adomat, Noushin Nabavi, Hakhamanesh Behmanesh, Beibei Zhai, Robert Dagil...> ;Cancers. 2021 Sep 6
98 citations
TMB or not TMB as a biomarker: That is the question
Alfredo Addeo, Alex Friedlaender, Giuseppe Luigi Banna, Glen J. Weiss> ;Critical Reviews in Oncology/hematology. 2021 Jul 1
44 citations
Distinct composition and metabolic functions of human gut microbiota are associated with cachexia in lung cancer patients.
Yueqiong Ni, Zoltan Lohinai, Yoshitaro Heshiki, Balazs Dome, Judit Moldvay, Edit Dulka, Gabriella Gálffy, Judit Berta, Glen J. Weiss, Morten Otto Alexander Sommer, Gia...> ;The ISME Journal. 2021 May 17
6 citations
Gut microbiome functionality might be associated with exercise tolerance and recurrence of resected early-stage lung cancer patients.
Andrea Marfil-Sánchez, Bastian Seelbinder, Yueqiong Ni, János Varga, Judit Berta, Virag Hollosi, Balazs Dome, Zsolt Megyesfalvi, Edit Dulka, Gabriella Gálffy, Glen J. ...> ;Plos One. 2021 Nov 18
20 citations
Metabolic modeling predicts specific gut bacteria as key determinants for Candida albicans colonization levels.
Mohammad Hassan Mirhakkak, Sascha Schäuble, Tilman E. Klassert, Sascha Brunke, Philipp Brandt, Daniel Loos, Ruben V. Uribe, Felipe Senne de Oliveira Lino, Yueqiong Ni,...> ;The ISME Journal. 2021 May 1
1 citations
Financial Conflicts of Interest Change After a High-Impact Clinical Trial Publication in Oncology.
Craig L. Cambridge, Emily Stern Gatof, Glen J. Weiss, Roger B. Davis> ;Journal of Patient-Centered Research and Reviews. 2020 Jul 27
12 citations
Association of extended dosing intervals or delays in pembrolizumab-based regimens with survival outcomes in advanced non-small cell lung cancer
Kartik Sehgal, Anushi Bulumulle, Heather Brody, Ritu R. Gill, Shravanti Macherla, Aleksandra Qilleri, Danielle C. McDonald, Cynthia R. Cherry, Meghan Shea, Mark S. Hub...> ;Clinical Lung Cancer. 2021 May 1
79 citations
Predictable modulation of cancer treatment outcomes by the gut microbiota
Yoshitaro Heshiki, Ruben Vazquez-Uribe, Jin Li, Yueqiong Ni, Scott Quainoo, Lejla Imamovic, Jun Li, Maria Rathmann Sørensen, Billy K. C. Chow, Glen J. Weiss, Aimin Xu,...> ;Microbiome. 2020 Mar 5
41 citations
First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low Dose Cyclophosphamide in Patients with Advanced Malignancies.
Kyriakos P. Papadopoulos, Melissa Lynne Johnson, Albert C. Lockhart, Kathleen N. Moore, Gerald Steven Falchook, Silvia C. Formenti, Aung Naing, Richard D. Carvajal, Le...> ;Clinical Cancer Research. 2020 Mar 1
77 citations
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures.
Alex Friedlaender, Alexander Drilon, Glen J. Weiss, Giuseppe Luigi Banna, Alfredo Addeo> ;Cancer Treatment Reviews. 2020 Apr 1
3 citations
Next-Generation Sequencing May Discriminate Extreme Long-term versus Short-term Survival in Patients with Metastatic Small Cell Lung Cancer (SCLC)
Zoltan Lohinai, Zsolt Megyesfalvi, Balazs Dome, Glen J. Weiss> ;Translational Oncology. 2019 Dec 1
5 citations
Tumor Mutation Burden-From Doubts to Concerns-In Reply.
Alfredo Addeo, Giuseppe Luigi Banna, Glen J. Weiss> ;JAMA Oncology. 2019 Dec 1
Lack of accountability in upholding authorship standards in prominent medical oncology clinical trials.
D.Y. Gui, Glen J. Weiss> ;Current Oncology. 2019 Oct 1
3 citations
Measuring tumor mutation burden in cell-free DNA: advantages and limits
Alfredo Addeo, Glen J. Weiss> ;Translational Lung Cancer Research. 2019 Aug 1
19 citations
Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer.
Zoltan Lohinai, Laura Bonanno, Aleksei Aksarin, Alberto Pavan, Zsolt Megyesfalvi, Balazs Santa, Virag Hollosi, Balazs Hegedus, Judit Moldvay, Pierfranco Conte, Mikhail...> ;Peerj. 2019 Jul 29
87 citations
Tumor Mutation Burden-From Hopes to Doubts.
Alfredo Addeo, Giuseppe Luigi Banna, Glen J. Weiss> ;JAMA Oncology. 2019 Jul 1
12 citations
A phase 1, open-label, dose-escalation trial of oral TSR-011 in patients with advanced solid tumours and lymphomas.
Chia-Chi Lin, Hendrik Tobias Arkenau, Sharon Lu, Jasgit C. Sachdev, Javier de Castro Carpeño, Monica M. Mita, Rafal Dziadziuszko, Wu Chou Su, Dmitri Bobilev, Lorraine ...> ;British Journal of Cancer. 2019 Jul 16
4 citations
Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis
Alfredo Addeo, Glen J. Weiss, Bishal Gyawali> ;JAMA Network Open. 2019 May 3
7 citations
Correction to: Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
Glen J. Weiss, Lisa Blaydorn, Julia Beck, Kirsten Bornemann-Kolatzki, Howard B. Urnovitz, E. Schütz, Vivek Khemka> ;Investigational New Drugs. 2019 Apr 24
3 citations
Discordant financial conflicts of interest disclosures between clinical trial conference abstract and subsequent publication.
Glen J. Weiss, Roger B. Davis> ;Peerj. 2019 Feb 11
Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer.
Weiss, G. J.,Addeo, A.> ;N. Engl. J. Med.. 2019 Feb 28
2 citations
A new era of treating advanced lung cancer is upon us
Glen J. Weiss> ;Translational Lung Cancer Research. 2018 Sep 1
2 citations
Correction: Performance of next-generation sequencing on small tumor specimens and/or low tumor content samples using a commercially available platform(PLoS ONE (2018)...
Scott Morris, Janakiraman Subramanian, Esma S. Gel, George C. Runger, Eric J. Thompson, David Mallery, Glen J. Weiss> ;Plos One. 2018 Jun 1
Join now to see all

Press Mentions

Oncotarget | Glypican-3 (GPC3) Is Associated with MCPyV-Negative Status and Impaired Outcome in Merkel Cell CarcinomaAugust 11th, 2022
CIRCULOGENE’s Precision Genomic Profiling Technology Featured in Three AACR 2019 AbstractsMarch 25th, 2019
CIRCULOGENE Appoints Dr. Glen J. Weiss as Chief Medical OfficerNovember 28th, 2017
Join now to see all